Beatrice Nardone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beatrice Nardone has a total of 363 co-authors. Here are the top co-authors by number of shared publications:
- Dennis P. West
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
35 shared publications Dennis P. West
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
24 shared publicationsKelsey A. Orrell
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
10 shared publicationsAnne E. Laumann
Department of Dermatology, Northwestern University, Chicago, Illinois
9 shared publications- Beatrice J. Edwards
The University of Texas MD Anderson Cancer Center, Houston, TX
8 shared publications - Giuseppe Micali
Dermatology Clinic University of Catania Catania Italy
8 shared publications
Latest Publications
- 12 October 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5)
Epidemiological analysis of mycosis fungoides (MF) in children and young adult patient populations: A population‐based analysis of the nationwide surveillance, epidemiology and end results (SEER) database
- 12 October 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5)
Epidemiological analysis of mycosis fungoides (MF) in children and young adult patient populations: A population‐based analysis of the nationwide surveillance, epidemiology and end results (SEER) database
- 10 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (8) , e711-e712
Rosacea of the scalp: Results from a retrospective and prospective randomized controlled study
- 10 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (8) , e711-e712
Rosacea of the scalp: Results from a retrospective and prospective randomized controlled study
- 1 October 2023
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 158 (5) , 388-394
Machine learning identification of patient clusters for cutaneous melanoma
Article: Machine learning identification of patient clusters for cutaneous melanoma - Italian Journal of Dermatology and Venereology 2023 Sep 26 - Minerva Medica - Journals
- 1 October 2023
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 158 (5) , 388-394
Machine learning identification of patient clusters for cutaneous melanoma
Article: Machine learning identification of patient clusters for cutaneous melanoma - Italian Journal of Dermatology and Venereology 2023 Sep 26 - Minerva Medica - Journals
- 21 October 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (4) , 667-669.e2
Noninvasive Evaluation of Diameter and Density of Dermal Papillae in Psoriatic and Healthy Skin Using Reflectance Confocal Microscopy: An Intrapatient Controlled Study and a Review
- 21 October 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (4) , 667-669.e2
Noninvasive Evaluation of Diameter and Density of Dermal Papillae in Psoriatic and Healthy Skin Using Reflectance Confocal Microscopy: An Intrapatient Controlled Study and a Review
- Open Access
- 17 October 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12) , e15900
Psoriasis exacerbation after COVID ‐19 vaccines: A brief report of the reported cases
Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID‐19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
- 17 October 2022
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12) , e15900
Open AccessPsoriasis exacerbation after COVID ‐19 vaccines: A brief report of the reported cases
Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID‐19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
- 7 April 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (6) , e15476
Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients
The aim of this meta‐analysis is to evaluate the safety of dupilumab use in the management of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of COVID‐19 infection. Seven databases (Google Scholar, Web of Science, Scopus, Virtual Health Library, PubMed, System for Information on Gray Literature in Europe, and The New York Academy of Medicine) were searched for eligible studies from inception until November 24, 2021. The quality of evidence was rated using the National Institute of Health and the Joanna Briggs Institute Critical Appraisal tool. Meta‐analysis was performed when the outcome is presented ≥2 studies. A total of 12 papers including 1611 AD patients were included in the study. The prevalence of COVID‐19 in AD treated with dupilumab was 3.2% (95% confidence interval [CI]: 1.7–5.8). COVID‐19 symptoms were reported by five patients who were presented with one or more of the following symptoms (fatigue, loss of taste and smell, runny nose, conjunctivitis, gastrointestinal symptoms, fever, cough, and dyspnea). Only three cases of COVID‐19 were hospitalized with a prevalence of 4.5%, while no patients with COVID‐19 died. Dupilumab is safe regarding the risk and the hazards of COVID‐19 in AD patients. Thus, based on these results continuation of dupilumab in AD patients is recommended, since dupilumab seems to be safe and crucial for a better disease outcome.
- 7 April 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (6) , e15476
Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients
The aim of this meta‐analysis is to evaluate the safety of dupilumab use in the management of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of COVID‐19 infection. Seven databases (Google Scholar, Web of Science, Scopus, Virtual Health Library, PubMed, System for Information on Gray Literature in Europe, and The New York Academy of Medicine) were searched for eligible studies from inception until November 24, 2021. The quality of evidence was rated using the National Institute of Health and the Joanna Briggs Institute Critical Appraisal tool. Meta‐analysis was performed when the outcome is presented ≥2 studies. A total of 12 papers including 1611 AD patients were included in the study. The prevalence of COVID‐19 in AD treated with dupilumab was 3.2% (95% confidence interval [CI]: 1.7–5.8). COVID‐19 symptoms were reported by five patients who were presented with one or more of the following symptoms (fatigue, loss of taste and smell, runny nose, conjunctivitis, gastrointestinal symptoms, fever, cough, and dyspnea). Only three cases of COVID‐19 were hospitalized with a prevalence of 4.5%, while no patients with COVID‐19 died. Dupilumab is safe regarding the risk and the hazards of COVID‐19 in AD patients. Thus, based on these results continuation of dupilumab in AD patients is recommended, since dupilumab seems to be safe and crucial for a better disease outcome.
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (3) , AB112
26681 Noninvasive evaluation of density and diameter of dermal papillae in psoriatic and healthy skin: An intrapatient controlled study
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (3) , AB112
26681 Noninvasive evaluation of density and diameter of dermal papillae in psoriatic and healthy skin: An intrapatient controlled study
- 11 July 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1191-1197
THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database
Background/Objective: Relative to adults, rates of melanoma are lower in children. Due to its rarity, it is difficult to assess the incidence, trends, and outcomes of this malignancy. Much of our understanding comes from single institution or regional cancer registries which may not be large enough to detect subtleties in the burden of pediatric melanoma.Methods: Data from the 2004 to 2016 National Cancer Database were analyzed; this database captures approximately 70% of all cancer diagnoses in the United States.Results: Our analysis consisted of 1903 cases. A majority were White (89.8%), the mean age was 12.4 years, and the ratio of females: males was 1.2:1.0. The most common anatomic location was the trunk (31.1%). Between 2004 and 2016, a decreasing trend in the number of new melanoma cases was observed. Comparing histologic subtype by age, there was an increased percentage of nodular and epithelioid and spindle cell tumors in the pre‐teen children and a greater percentage of superficial spreading tumors in teenagers. Overall, a majority of cases were stage 0 or I (56.9%), with relatively few stage IV cases (2.0%). A 5‐year all‐cause survival of greater than 90% was observed for stage I‐III tumors, with stage IV tumors having a 5‐year all‐cause survival of 34.4%.Conclusion: Comparable to previous studies, pediatric melanoma occurred most often in Whites, females, and adolescents. However, we detected a decreasing trend in new cases, noted differences between histologic subtype and age, and observed a 5‐year all‐cause survival rate of greater than 90% for stage I‐III tumors.
- 11 July 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1191-1197
THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database
Background/Objective: Relative to adults, rates of melanoma are lower in children. Due to its rarity, it is difficult to assess the incidence, trends, and outcomes of this malignancy. Much of our understanding comes from single institution or regional cancer registries which may not be large enough to detect subtleties in the burden of pediatric melanoma.Methods: Data from the 2004 to 2016 National Cancer Database were analyzed; this database captures approximately 70% of all cancer diagnoses in the United States.Results: Our analysis consisted of 1903 cases. A majority were White (89.8%), the mean age was 12.4 years, and the ratio of females: males was 1.2:1.0. The most common anatomic location was the trunk (31.1%). Between 2004 and 2016, a decreasing trend in the number of new melanoma cases was observed. Comparing histologic subtype by age, there was an increased percentage of nodular and epithelioid and spindle cell tumors in the pre‐teen children and a greater percentage of superficial spreading tumors in teenagers. Overall, a majority of cases were stage 0 or I (56.9%), with relatively few stage IV cases (2.0%). A 5‐year all‐cause survival of greater than 90% was observed for stage I‐III tumors, with stage IV tumors having a 5‐year all‐cause survival of 34.4%.Conclusion: Comparable to previous studies, pediatric melanoma occurred most often in Whites, females, and adolescents. However, we detected a decreasing trend in new cases, noted differences between histologic subtype and age, and observed a 5‐year all‐cause survival rate of greater than 90% for stage I‐III tumors.
- 1 March 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (3) , 862-864
Age and sex differences for malignant melanoma in the pediatric population—childhood versus adolescence: analysis of current nationwide data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program
- 1 March 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (3) , 862-864
Age and sex differences for malignant melanoma in the pediatric population—childhood versus adolescence: analysis of current nationwide data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program